TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways
© 2022. The Author(s)..
The pathogenesis of lung cancer, the most common cancer, is complex and unclear, leading to limited treatment options and poor prognosis. To provide molecular insights into lung cancer development, we investigated the function and underlying mechanism of SH2B3 in the regulation of lung cancer. We indicated SH2B3 was diminished while TGF-β1 was elevated in lung cancer tissues and cells. Low SH2B3 level was correlated with poor prognosis of lung cancer patients. SH2B3 overexpression suppressed cancer cell anoikis resistance, proliferation, migration, invasion, and EMT, while TGF-β1 promoted those processes via reducing SH2B3. SH2B3 bound to JAK2 and SHP2 to repress JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling pathways, respectively, resulting in reduced cancer cell anoikis resistance, proliferation, migration, invasion, and EMT. Overexpression of SH2B3 suppressed lung cancer growth and metastasis in vivo. In conclusion, SH2B3 restrained the development of anoikis resistance and EMT of lung cancer cells via suppressing JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling cascades, leading to decreased cancer cell proliferation, migration, and invasion.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Cell death & disease - 13(2022), 5 vom: 19. Mai, Seite 472 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wang, Li-Na [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 23.05.2022 Date Revised 12.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41419-022-04890-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM341124133 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM341124133 | ||
003 | DE-627 | ||
005 | 20231226011045.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41419-022-04890-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1137.xml |
035 | |a (DE-627)NLM341124133 | ||
035 | |a (NLM)35589677 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wang, Li-Na |e verfasserin |4 aut | |
245 | 1 | 0 | |a TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 23.05.2022 | ||
500 | |a Date Revised 12.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a The pathogenesis of lung cancer, the most common cancer, is complex and unclear, leading to limited treatment options and poor prognosis. To provide molecular insights into lung cancer development, we investigated the function and underlying mechanism of SH2B3 in the regulation of lung cancer. We indicated SH2B3 was diminished while TGF-β1 was elevated in lung cancer tissues and cells. Low SH2B3 level was correlated with poor prognosis of lung cancer patients. SH2B3 overexpression suppressed cancer cell anoikis resistance, proliferation, migration, invasion, and EMT, while TGF-β1 promoted those processes via reducing SH2B3. SH2B3 bound to JAK2 and SHP2 to repress JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling pathways, respectively, resulting in reduced cancer cell anoikis resistance, proliferation, migration, invasion, and EMT. Overexpression of SH2B3 suppressed lung cancer growth and metastasis in vivo. In conclusion, SH2B3 restrained the development of anoikis resistance and EMT of lung cancer cells via suppressing JAK2/STAT3 and SHP2/Grb2/PI3K/AKT signaling cascades, leading to decreased cancer cell proliferation, migration, and invasion | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a GRB2 Adaptor Protein |2 NLM | |
650 | 7 | |a GRB2 protein, human |2 NLM | |
650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
650 | 7 | |a STAT3 protein, human |2 NLM | |
650 | 7 | |a Transforming Growth Factor beta1 |2 NLM | |
650 | 7 | |a JAK2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a Janus Kinase 2 |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a Proto-Oncogene Proteins c-akt |2 NLM | |
650 | 7 | |a EC 2.7.11.1 |2 NLM | |
700 | 1 | |a Zhang, Zi-Teng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Li |e verfasserin |4 aut | |
700 | 1 | |a Wei, Hai-Xiang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Tao |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Li-Ming |e verfasserin |4 aut | |
700 | 1 | |a Lin, Hang |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Heng |e verfasserin |4 aut | |
700 | 1 | |a Wang, Shao-Qiang |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cell death & disease |d 2010 |g 13(2022), 5 vom: 19. Mai, Seite 472 |w (DE-627)NLM202030881 |x 2041-4889 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2022 |g number:5 |g day:19 |g month:05 |g pages:472 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41419-022-04890-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2022 |e 5 |b 19 |c 05 |h 472 |